The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer:
Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

CME Available: https://auau.auanet.org/node/39542
Release Date: December, 2023
Expiration Date: December, 2024

LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment.
2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches.
3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up.

ACKNOWLEDGEMENTS:
Support provided by independent educational grants from: 
AstraZeneca
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC 
Lantheus Medical Imaging
Merck & Co., Inc.